Skip to Content

Durvalumab Pregnancy and Breastfeeding Warnings

Durvalumab is also known as: Imfinzi

Durvalumab Pregnancy Warnings

The PD-1/PD-L1 pathway plays a central role in preserving pregnancy by maintaining maternal immune tolerance to the fetus. In animal studies, disruption of PD-L1 signaling resulted in an increase in fetal loss. Exposure to this drug in pregnant animals at levels approximately 6 to 20 times higher than the recommended human dose resulted in premature delivery, fetal loss (abortion and stillbirth), and increased neonatal deaths. This drug crosses the placenta. Immune-mediated disorders have been reported in animal studies. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

The manufacturer makes no recommendation regarding use during pregnancy. US FDA pregnancy category: Not assigned. Risk Summary: This drug caused an increase in premature delivery, fetal loss, and premature neonatal death in animal studies. Human immunoglobulin G1 (IgG1) crosses the placental barrier; therefore, this drug can be transmitted from the mother to the developing fetus. Comments: -This drug can harm a developing fetus. -Women of childbearing potential should use effective contraception during therapy and for at least 3 months after the last dose. -If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Durvalumab Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Yes Comments: -The effects in the nursing infant are unknown; however, this drug has been associated with premature neonatal death in animal breastfeeding studies. -Women should be advised not to breastfeed during therapy and for at least 3 months after the last dose.

See references

References for pregnancy information

  1. "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.